Antibody Conjugation of a Chimeric BET Degrader Enables <i>in vivo</i> Activity

Thomas H. Pillow(Genesys (United States)), Peter S. Dragovich(Genesys (United States)), Shang‐Fan Yu(Genesys (United States)), Tracy Kleinheinz(Genesys (United States)), Brandon Latifi(Genesys (United States)), Isabel Figueroa(Merck & Co., Inc., Rahway, NJ, USA (United States)), Karen E. Gascoigne(Genesys (United States)), Jack Sadowsky(Genesys (United States)), Cong Wu(Second Military Medical University), Chun Sing Li(WuXi AppTec (China)), Rebecca K. Rowntree(Genesys (United States)), Donglu Zhang(Genesys (United States)), Pragya Adhikari(Genesys (United States)), Douglas D. Leipold(Genesys (United States)), Katherine R. Kozak(Genesys (United States)), Gauri Deshmukh(Genesys (United States)), Zijin Xu(WuXi AppTec (China)), Aimee O’Donohue(Genesys (United States)), Amrita V. Kamath(Genesys (United States)), Hongyan Zhang(Xintai People's Hospital), Xinxin Wang(Chinese PLA General Hospital), Jinhua Chen(WuXi AppTec (China)), Hui Yao(Wannan Medical College), Xiaoyu Zhu(WuXi AppTec (China)), Hao Zhou(Institute of Chemical Industry of Forest Products), Ruina Li(Genesys (United States)), Susan Kaufman(Genesys (United States)), Robert A. Blake(Exelixis (United States)), John Wai(WuXi AppTec (China)), Richard Zang(Genesys (United States)), Geoffrey Del Rosario(Genesys (United States)), Melinda M. Mulvihill(Genesys (United States))
ChemMedChem
October 31, 2019
Cited by 193


Related Papers